Display options
Cite
Kitajima Y, Miyazaki K. The Critical Impact of HIF-1a on Gastric Cancer Biology. Cancers (Basel). 2013;5(1):15-26doi: 10.3390/cancers5010015.
Kitajima, Y., & Miyazaki, K. (2013). The Critical Impact of HIF-1a on Gastric Cancer Biology. Cancers, 5(1), 15-26. https://doi.org/10.3390/cancers5010015
Kitajima, Yoshihiko, and Miyazaki, Kohji. "The Critical Impact of HIF-1a on Gastric Cancer Biology." Cancers vol. 5,1 (2013): 15-26. doi: https://doi.org/10.3390/cancers5010015
Kitajima Y, Miyazaki K. The Critical Impact of HIF-1a on Gastric Cancer Biology. Cancers (Basel). 2013 Jan 10;5(1):15-26. doi: 10.3390/cancers5010015. PMID: 24216696; PMCID: PMC3730315.
Copy Download .nbib Format: NLM
Share it on

Cancers (Basel). 2013 Jan 10;5(1):15-26. doi: 10.3390/cancers5010015.

The Critical Impact of HIF-1a on Gastric Cancer Biology.

Cancers

Yoshihiko Kitajima, Kohji Miyazaki

Affiliations

  1. Department of Surgery, Saga University Faculty of Medicine, Saga 849-8501, Japan. [email protected].

PMID: 24216696 PMCID: PMC3730315 DOI: 10.3390/cancers5010015

Abstract

Hypoxia inducible factor-1 (HIF-1) monitors the cellular response to the oxygen levels in solid tumors. Under hypoxia conditions, HIF-1a protein is stabilized and forms a heterodimer with the HIF-1β subunit. The HIF-1 complex activates the transcription of numerous target genes in order to adapt the hypoxic environment in human cancer cells. In gastric cancer patients, HIF-1a activation following extended hypoxia strongly correlates with an aggressive tumor phenotype and a poor prognosis. HIF-1a activation has been also reported to occur via hypoxia-independent mechanisms such as PI3K/AKT/mTOR signaling and ROS production. This article argues for the critical roles of HIF-1a in glucose metabolism, carcinogenesis, angiogenesis, invasion, metastasis, cell survival and chemoresistance, focusing on gastric cancer.

References

  1. Cancer. 1996 Mar 1;77(5):858-63 - PubMed
  2. Pancreas. 2002 Aug;25(2):122-9 - PubMed
  3. Proc Natl Acad Sci U S A. 2009 Mar 17;106(11):4260-5 - PubMed
  4. Nat Rev Cancer. 2002 Jan;2(1):38-47 - PubMed
  5. Cancer Sci. 2008 Jan;99(1):121-8 - PubMed
  6. Br J Cancer. 2010 Mar 2;102(5):898-907 - PubMed
  7. Cancer Sci. 2010 Jul;101(7):1653-60 - PubMed
  8. Surgery. 1999 Feb;125(2):195-201 - PubMed
  9. Mol Cell. 2005 Mar 18;17(6):793-803 - PubMed
  10. Int J Cancer. 2010 Aug 15;127(4):820-9 - PubMed
  11. Clin Cancer Res. 2000 Feb;6(2):622-30 - PubMed
  12. Cancer Sci. 2008 Jul;99(7):1341-7 - PubMed
  13. Mol Cancer. 2010 Nov 13;9:293 - PubMed
  14. Science. 1956 Feb 24;123(3191):309-14 - PubMed
  15. Trends Pharmacol Sci. 2012 Apr;33(4):207-14 - PubMed
  16. Trends Mol Med. 2002;8(4 Suppl):S62-7 - PubMed
  17. J Biol Chem. 2008 Jun 6;283(23):15807-15 - PubMed
  18. Brain Res Bull. 1995;37(4):417-29 - PubMed
  19. Int J Cancer. 2003 Mar 10;104(1):44-53 - PubMed
  20. Carcinogenesis. 2008 Jan;29(1):44-51 - PubMed
  21. Int J Cancer. 2010 Sep 1;127(5):1158-71 - PubMed
  22. Int J Oncol. 2006 Dec;29(6):1533-9 - PubMed
  23. J Biol Chem. 2009 Jun 19;284(25):16767-16775 - PubMed
  24. Curr Opin Genet Dev. 2010 Feb;20(1):51-6 - PubMed
  25. Cell Metab. 2006 Mar;3(3):187-97 - PubMed
  26. Int J Cancer. 2006 Dec 15;119(12):2750-9 - PubMed
  27. Br J Cancer. 2007 Jan 15;96(1):95-103 - PubMed
  28. Cancer Res. 2008 Dec 15;68(24):10113-20 - PubMed
  29. Biochem Biophys Res Commun. 2012 May 11;421(3):538-43 - PubMed
  30. Exp Mol Med. 2009 Jan 31;41(1):51-8 - PubMed
  31. Cancer Sci. 2010 May;101(5):1141-6 - PubMed
  32. Int J Cancer. 2007 Apr 15;120(8):1803-10 - PubMed
  33. Clin Cancer Res. 2010 Dec 15;16(24):5928-35 - PubMed
  34. Cancer Biol Ther. 2010 Aug 15;10(4):383-5 - PubMed
  35. Br J Cancer. 2009 Mar 10;100(5):772-81 - PubMed
  36. PLoS One. 2010 Aug 10;5(8):e12038 - PubMed
  37. J Natl Cancer Inst. 2004 Jun 16;96(12):946-56 - PubMed
  38. Eur J Gynaecol Oncol. 2012;33(3):285-90 - PubMed

Publication Types